CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team’s dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment.
We are proud to announce our significant contribution to a seminal scientific paper focused on Antibody-Drug Conjugates (ADCs) in the clinical landscape. The paper delves, among other aspects, into an extensive analysis of the physicochemical properties of ADC payloads, yielding crucial insights pivotal for the strategic design and advancement of ADC therapies.
As a leader in innovative biotechnological solutions, CancerAppy team played a high relevant role in the collaborative effort that culminated in this comprehensive examination. The paper’s findings promise to revolutionize the development and optimization of ADCs, offering a clearer understanding of the relationship between payload properties and therapeutic efficacy.
ADCs represent a pivotal therapeutic advancement, effectively applied across diverse clinical scenarios. Comprising antibodies targeting tumor-associated antigens (TAAs), cytotoxic payloads, and binding linkers, ADCs have primarily focused research on target identification, antibody design, and linker optimization, leaving other critical clinical facets understudied. In this work, the researches performed a comprehensive assessment of approved ADCs and analyzed properties such as payload physicochemical attributes, potency, drug antibody ratio (DAR), exposure–response correlations, and development strategies. Optimal clinical candidates feature ideal payload properties and cleavable linkers, particularly impactful in low TAA expression contexts. Additionally, early clinical tactics, including altered dosing schedules, aim for enhanced efficiency. This analysis emphasizes overlooked facets essential for ADC cancer development, proposing avenues for refinement.
Dr. Elisa Poyatos, Chief Scientific Officer at CancerAppy, expressed enthusiasm about the company’s involvement in this groundbreaking endeavor, stating, “Our team’s commitment to pushing the boundaries of scientific knowledge has motivated our dive into the intricate details of ADCs. By conducting thorough analysis and partnering with respected researchers, we’ve uncovered crucial understandings about the physicochemical characteristics of ADC payloads. This knowledge might empower the industry to create therapies that are more effective and impactful.”
This collaborative scientific effort underscores CancerAppy’s commitment to pioneering advancements in biotechnology and reinforces its dedication to fostering innovation within the industry.
The complete work has been published in the Journal of Hematology & Oncology, with an impact factor of 28.5 (2022); and can be read with open access at the following link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01519-0
For media inquiries, please contact firstname.lastname@example.org
CancerAppy’s groundbreaking study at ESMO Congress (Oct ’23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.
CancerAppy has contributed to a groundbreaking study unveiled at the esteemed ESMO Congress in Madrid (October 2023) Our pioneering biotech, harnessing the power of AI in Drug Design, has taken a major step in understanding immune cell populations within tumor environments, specifically the regulatory CD4+ T cells (Tregs), and their profound impact on tumor immune responses.
Intriguing insights emerged from the analysis of breast cancer datasets, unveiling a mere 0.5% of the transcriptome intricately linked to Treg presence. Notably, we unearthed four common transcripts shared across various cancer subtypes (BIRC6, MAP3K2, USP4, SMG1). Additionally, our study highlighted ten upregulated genes, predominantly expressed at cell membranes, intricately correlated with PDL1/PD1 expression or the presence of macrophages in basal-like/HER2+ tumors.
Several genes—MSR1, CD80, OLR1, ABCA1, TMEM245, ATP13A3—emerged as potential predictors of favorable outcomes and responses to anti-PD(L)1/CTLA4 therapies, illuminating promising avenues to fortify anti-tumor immune activity.
This research highlights the immense potential of modulating Treg responses, offering a compelling glimpse into the future of cancer treatment. Furthermore, it highlights the usefulness of in-depth treatment of existing and available data for decision-making in the design of new drugs and treatments.
Stay tuned as we continue to validate and unlock the transformative impact of these findings. #ESMO2023 #AIDrugDiscovery #CancerResearch #Immunotherapy
We are delighted to announce our first collaborative scientific research article. At CancerAppy, our commitment to harnessing the power of AI in cancer drug discovery has led us to join forces with leading researchers in the field. This groundbreaking collaboration marks the beginning of an exciting journey, in which our collective goal is to unravel the mysteries of cancer and develop innovative solutions.
In the pages of our inaugural joint publication, titled “Guanylation Reactions for the Rational Design of Cancer
Therapeutic Agents” shows the potential collaboration that cancerappy offers to researchers by making our innovative AI platform available to them.
This milestone is not just about the document itself; is a testament to the strength of collaboration and the pursuit of knowledge for the common good. We are dedicated to the pursuit of innovative discoveries and this first research work represents a pivotal moment in our journey.
Stay tuned for more updates on this exciting collaboration, as we continue to push the boundaries of what is possible in the world of cancer research. Together, we are moving toward a better future for those affected by this devastating disease.
We’re excited to be part of BioSpain 2023, and despite our packed schedule, we welcome you to connect with us at the BasqueHealthCluster booth. Explore our groundbreaking work in the world of biotechnology and cancer research. See you there!.